Summary
Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States, Europe, and Asia. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist used for the treatment of chronic obstructive pulmonary disease (COPD). Its product portfolio also include Izencitinib, a gut-selective pan-janus kinase (JAK) inhibitor that is in Phase IIb/III clinical trials for the treatment of rheumatoid arthritis, myelofibrosis, and ulcerative colitis, as well as for a range of inflammatory intestinal diseases, including ulcerative colitis and Crohn's disease. In addition, the company's product portfolio comprise Ampreloxetine, an investigational norepinephrine reuptake inhibitor that has completed Phase III study for neurogenic orthostatic hypotension; Nezulcitinib, a lung-selective, nebulized JAK inhibitor, which is in Phase II clinical development for the potential treatment of hospitalized patients with acute lung injury caused by COVID-19; Inhaled ALK5i, a potential inhaled anti-fibrotic agent that is in Phase I for the treatment of idiopathic pulmonary fibrosis; and TD-5202, an investigational, orally administered, gut-selective, irreversible JAK3 inhibitor that is in Phase I clinical study for treatment of inflammatory intestinal diseases. Further, it offers TRELEGY for the treatment of COPD and asthma; Velusetrag, an oral and investigational medicine for gastrointestinal motility disorders; and Selective 5-HT4 Agonist for treatment of gastrointestinal motility disorders. It has a licensing and collaboration agreements with Pfizer Inc., Viatris Inc., Janssen Biotech, Inc., Alfasigma S.p.A, and Takeda Pharmaceutical Company Limited. Theravance Biopharma, Inc. was incorporated in 2013 and is based in George Town, the Cayman Islands.
History
Theravance Biopharma was founded in 1996 as Theravance, Inc., a research-based pharmaceutical company. In December 2012, the company pursued two distinct paths: gentamicin-based antibiotics and all other programs, including, but not limited to, respiratory, bacterial infections, urology, and gastrointestinal programs. In January 2013, Theravance restructured into two companies — Theravance Biopharma, a clinical-stage biopharmaceutical company dedicated to bringing tailored medicines to patients, and Royalty Pharma, a leader in the field of biopharmaceutical royalty and finance.
Mission
At Theravance Biopharma, our mission is to bring innovative medicines to patients. We are focused on addressing some of the world’s most complex and challenging diseases and conditions, and we strive to discover, develop and commercialize therapies that can improve human health.
Vision
We are a leading global biopharmaceutical company dedicated to bringing tailored and best-in-class therapies to patients with serious and life-threatening conditions. Our team is passionate, driven and committed to creating emerging medicines that can help make a difference in patients’ lives.
Key Team
Dr. Richard A. Graham Ph.D. (Sr. VP of R&D)
Ms. Stacy L. Pryce (Sr. VP & Chief Strategy Officer)
Ms. Gail B. Cohen (VP of Corp. Communications & Investor Relations)
Mr. Brett A. Grimaud Esq. (Sr. VP, Gen. Counsel & Sec.)
Recognition and Awards
Theravance Biopharma has received many awards and accolades since its establishment, including being named one of the 2014 TechAmerica 50 companies, being listed on Fortune’s List of Most Admired Companies in the Biotech & Pharmaceuticals category, and being recognized by FierceBiotech as one of the Fierce 15. Most recently, Theravance Biopharma was named a Forbes 2016 Best Biotech Employer.
References
Cayman Islands 